Integra Lifesciences Holdings Corp (IART) is Resumed by JP Morgan to Overweight

Integra Lifesciences Holdings Corp (IART) was Resumed by JP Morgan to “Overweight”. JP Morgan advised their investors in a research report released on Jul 13, 2016.

Many Wall Street Analysts have commented on Integra Lifesciences Holdings Corp. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 74 from a previous price target of $70 .

On the company’s financial health, Integra Lifesciences Holdings Corp reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.73. The company had revenue of $236.80 million for the quarter, compared to analysts expectations of $230.83 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 EPS.

Integra Lifesciences Holdings Corp closed down -0.95 points or -1.17% at $80.5 with 5,48,496 shares getting traded on Monday. Post opening the session at $81.82, the shares hit an intraday low of $80.41 and an intraday high of $81.82 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Jun 2, 2016, James M Sullivan (director) sold 5,260 shares at $73.82 per share price. According to the SEC, on May 11, 2016, John Mooradian (Corp VP, Global Ops & Supp Chn) sold 7,653 shares at $67.04 per share price. On May 11, 2016, Joseph Vinhais (Corp VP,Global Qlty Assurance) sold 972 shares at $73.36 per share price, according to the Form-4 filing with the securities and exchange commission.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.

Integra Lifesciences Holdings Corp

Leave a Reply

Integra Lifesciences Holdings Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Integra Lifesciences Holdings Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.